Gong is part of the laboratory of William Pao, M.D., Ph.D. Their studies were funded by the Doris Duke Charitable Foundation and the Labrecque Foundation. ABT-737 is under development by Abbott Laboratories, Inc.
TRAIL-receptor antibodies synergize with chemotherapy to enhance anti-tumor activity in cholangiocarcinoma: Abstract B 50.
A common chemotherapy regimen, when given before either one of two engineered human antibodies, greatly increases the effectiveness of the antibodies against cholangiocarcinoma (CCA), a rare and deadly cancer of the ducts that drain bile from the liver, say researchers from Human Genome Sciences, Inc., a biopharmaceutical research company based in Rockville, Maryland. If their findings in cell culture and animal models of CCA can be applied to humans, the combination of cisplatin, 5-fluorouracil or gemcitabine with a TRAIL-receptor antibody would be the first effective treatment for this disease, they say.
The two antibodies react with different, yet related, cell surface proteins called TRAIL-R1 and TRAIL-R2, which are common to many human cancers. While they are distinct receptors, these two receptors both receive signals that activate biochemical pathways leading to programmed cell death, the researchers say. The TRAIL-R1 antibody (known as mapatumumab) and TRAIL-R2 antibody (lexatumumab) are both being evaluated in clinical trials by Human Genome Sciences.
Many cancers use the TRAIL pathway as a preferred way to die a dominant biochemical pathway and we are in the process of exploring how we can better activate the TRAIL pathways to enhance cell death in the tumor cell, said Robin C. Humphreys, Ph.D., associate director in the Oncology Research Department at Human Genome Sciences. When we pre-treat CCA cell lines with conventional chemotherapies, the drugs seem to in
|Contact: Greg Lester|
American Association for Cancer Research